FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer
14 Mayo 2024 - 5:00AM
Business Wire
Agreement will leverage both companies’
proprietary discovery & development platforms to create a new
class of alpha radioligand therapeutics that will maximize efficacy
and transform patient outcomes
ARTBIO to leverage AlphaDirect™ platform to
enable development and distributed manufacturing of 212Pb alpha
radioligand therapies
FogPharma to leverage its proprietary Helicon™
platform of ultratunable peptides to drive invention of the ideal
peptide to carry 212Pb to tumors
FogPharma®, a clinical-stage biopharmaceutical company dedicated
to delivering a new class of therapies that go beyond the limits of
currently available medicines using its Helicon™ peptide platform,
and ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical
company developing a new class of 212Pb alpha radioligand therapies
(ARTs), announced a collaboration to co-develop Helicon-enabled
ARTs (HEARTs) to transform outcomes for patients with multiple
types of cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240514522695/en/
ARTBIO and FogPharma will co-develop novel HEARTs against
multiple targets, leveraging FogPharma’s field-leading Helicon
platform of tunable stabilized α-helical peptides and ARTBIO’s
AlphaDirect™ platform for the development of ARTs using the
best-in-class isotope, 212Pb. ARTs with 212Pb have the ideal
clinical profile due to a short half-life that delivers maximal
energy into tumors with high stability and the ability to image
with SPECT/CT. The synergy of these two powerful platforms offers
promising potential to create next-generation ARTs with properties
ideal for precise delivery to tumors.
“Our AI-enabled Helicon platform provides an unprecedented level
of chemical flexibility and diversity for modifying the crucial
chemical and biological properties of peptides, a capability that
we have leveraged to address previously undruggable protein:protein
interactions inside the cell. We are thrilled to begin our
collaboration with ARTBIO, wherein we extend the use of our
Helicons to bind extracellular proteins and use our Helicons to
finely tune distribution and elimination properties, paving the way
for a new safe and effective category of targeted radioligand
therapy,” stated Mathai Mammen, M.D., Ph.D., CEO of FogPharma. “Our
aim is to revolutionize outcomes for cancer patients in critical
need.”
“Alpha radioligand therapy, and 212Pb in particular, has shown
tremendous promise as a new class of radiopharmaceuticals. This
collaboration with FogPharma enables ARTBIO to advance
next-generation therapeutics specifically designed to treat solid
tumors,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO. “FogPharma has
a shared vision of radically changing the current treatment
paradigms for cancers, and together we will fuse science,
technology, and collective passion to improve patient
outcomes.”
The partners will contribute equally to the collaboration across
research, development and commercialization phases; additional
financial terms are undisclosed.
About FogPharma® FogPharma is a biopharmaceutical company
pioneering the discovery and development of Helicon™ therapeutics,
which are peptides capable of efficient cell entry and modulation
of both protein-protein and protein-DNA interactions. Through
Helicon therapeutics, FogPharma is poised to revolutionize the
medical possibilities for patients by precisely drugging
intracellular targets long understood to be significant drivers of
disease but never before drugged due to the limitations of existing
drug modalities to act within the cell. FOG-001, the company’s
first-in-class TCF-blocking β-catenin inhibitor, is being evaluated
in a Phase 1/2 study for patients with advanced solid tumors,
including colorectal cancer. FogPharma is fully leveraging the
unprecedented potential Helicons present by deploying proprietary,
custom-built machine learning and computational methods as part of
its discovery and development process. FogPharma has raised more
than $500 million to date from leading life sciences investors.
FogPharma is headquartered in Cambridge, Mass. For more
information, please visit: www.fogpharma.com.
About ARTBIO ARTBIO is a clinical-stage
radiopharmaceutical company redefining cancer care by creating a
new class of alpha radioligand therapies (ARTs). The unique ARTBIO
approach selects the optimal alpha-precursor isotope (Pb212) and
tumor-specific targets to create therapeutics with the potential
for highest efficacy and safety. The company's AlphaDirect™
technology, a first-of-its-kind 212Pb isolation method, enables a
distributed manufacturing approach for the reliable production and
delivery of ARTs. ARTBIO is advancing multiple pipeline programs
with lead program AB001 currently in first in human trials. ARTBIO
is shaped by a long-standing scientific legacy with nearly a
century of pioneering work in radiation therapy conducted at the
University of Oslo and Norway’s Radium Hospital. For more
information, visit www.artbio.com, and follow us on LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514522695/en/
FogPharma Media Contact Ten Bridge Communications Lisa
Raffensperger lisa@tenbridgecommunications.com
ARTBIO Media Contact Marites Coulter
marites.coulter@vergescientific.com